Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury

Status Completed

Clinical Trial Summary

This study examines the hypothesis that administering intravenous fish oil, in lieu of intravenous soybean oil, can ameliorate the progression of PN-associated cholestatic liver disease in pediatric patients with elevated direct bilirubin requiring PN for more than 30 days.

Clinical Trial Description

In the United States, patients dependent upon parenteral nutrition (PN) receive parenteral fat emulsions composed of soybean oils. Lipids are necessary in PN dependent patients due to their high caloric value and essential fatty acid content. They have been implicated in predisposing patients to PN associated liver disease. Phytosterols such as those contained in soybean oils are thought to have a deleterious effect on biliary secretion.

Children requiring prolonged PN are at risk for developing PN associated liver disease. We hypothesize that although omega-6 fatty acid emulsions prevent fatty acid deficiency, they are not cleared in a manner similar to enteral chylomicrons and therefore accumulate in the liver and resulting in steatotic liver injury. We further hypothesize that a fat emulsion comprised of omega-3 fatty acids (i.e., fish oil) such as Omegaven™ would be beneficial in the management of steatotic liver injury by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum. Animal studies have shown that IV fat emulsions (IFE) such as fish oil that are high in eicosapentaenic and docashexaaenoic acid reduce impairment of bile flow which is seen in cholestasis caused by conventional fat emulsions. Intravenous omega three fatty acids may be well tolerated and might reduce the inflammatory effect in the liver of prolonged PN exposure and could potentially reverse any hepatic dysfunction due to PN/IFE use. By administering Omegaven™ in place of conventional phytosterol/soybean fat emulsions we may reverse or prevent the progression of PN associated cholestasis and thus allow the patient to be maintained on adequate PN until they are able to ingest adequate nutrition enterally. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01089426
Study type	Interventional
Source	Children's Hospital Los Angeles
Contact
Status	Completed
Phase	N/A
Start date	September 2008
Completion date	April 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06244550` - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	N/A
Recruiting	`NCT05229328` - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
Recruiting	`NCT06080308` - Liver Ischemia-reperfusion Injury and Clinical Data Analysis
Recruiting	`NCT05155358` - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke
Terminated	`NCT04004884` - Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)
Recruiting	`NCT01802996` - Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury	Phase 4
Active, not recruiting	`NCT05882214` - Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink	N/A
Completed	`NCT04934384` - The Role of Prehospital eFAST in Accelerating Time to Diagnostics or Definitive Treatment in the Emergency Department
Recruiting	`NCT03039062` - Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy	N/A
Completed	`NCT00694499` - Non-Operative Management of High Grade Blunt Hepatic Injury: Clinical Complications and the Role of Collateral Damage	N/A
Recruiting	`NCT04937868` - Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Completed	`NCT06249646` - Contained Hepatic Vascular Injuries Following Liver Trauma
Recruiting	`NCT06402981` - A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients
Terminated	`NCT02915081` - Blue Light Therapy for Liver Surgery	N/A
Completed	`NCT03667157` - Liver Function After Intravenous Methylprednisolone Administration	Phase 4
Completed	`NCT03281265` - A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China	N/A
Completed	`NCT04257240` - Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
Not yet recruiting	`NCT02808299` - Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection	N/A
Not yet recruiting	`NCT06258525` - SAMe in Prevention of Oxaliplatin-associated Liver Injury	Phase 2
Active, not recruiting	`NCT06298318` - Metabolic Changes in Healthy Subjects With Acute Binge Drink	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.